Novo Nordisk A/S, already reeling from pricing pressure in its diabetes business, is now feeling the heat in the $8 billion market for treating hemophilia, a rare bleeding disorder.
The Danish company is bracing for competition for NovoSeven, a blockbuster that generated $1.5 billion in sales last year, from Roche Holding AG. The Swiss drugmaker is in final stages of testing a new drug that promises to chip away at a part of the market long dominated by the 20-year-old medicine.
